Skip to main content
. 2020 Mar 18;14(5):964–973. doi: 10.1002/1878-0261.12660

Table 3.

The predictor for nonresponse to bevacizumab combination therapy applied to the training cohort.

Training cohort Predictor for nonresponse

Negative test for nonresponse

Methylated (≥ 12%)

Positive test for nonresponse

Nonmethylated (< 12%)

Nonresponse 32 (56%) 19 (95%)
Response 25 (44%) 1 (5%)
Total 57 20